Immunologist and virologist
Galit Alter is an immunologist and virologist, professor of medicine at Harvard Medical School , and group leader at the Ragon Institute of MGH, MIT and Harvard . She is known for her work on the expansion of particular natural killer cell subtypes in response to HIV-1 infection.[ 4] [ 5] She has also contributed to the understanding of how SARS-CoV-2 antibody titers correlate with sustained humoral protection , including identifying coordinated immune cell-antibody signatures that may predict COVID-19 infection outcome.[ 2] [ 6]
From October 2022 to October 2024 she joined Moderna on a sabbatical from the Ragon Institute to lead the immunology group within Infectious Disease Research.[ 7]
References
^ "Alter - Ragon Institute of MGH, MIT and Harvard" . ragoninstitute.org . Retrieved 2021-02-23 .
^ a b Scanlon, Jessie (2020-12-10). "Galit Alter: Connecting scientists to speed up the COVID-19 fight" . bostonglobe.com . Retrieved 2021-02-23 .
^ "Virology Faculty Member - Galit Alter" . hms.harvard.edu . Retrieved 2021-02-23 .
^ Alter, Galit; Malenfant, Jessica M; Altfeld, Marcus (2004). "CD107a as a functional marker for the identification of natural killer cell activity" . J Immunol Methods . 294 (1– 2): 15– 22. doi :10.1016/j.jim.2004.08.008 . PMID 15604012 . Retrieved 1 April 2021 .
^ Alter, Galit; Martin, Maureen P; et al. (26 Nov 2007). "Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes" . J Exp Med . 204 (12): 3027– 36. doi :10.1084/jem.20070695 . PMC 2118524 . PMID 18025129 .
^ Atyeo, Caroline; Fischinger, Stephanie; Zohar, Tomer...; Alter, Galit (15 September 2020). "Distinct Early Serological Signatures Track with SARS-CoV-2 Survival" . Immunity . 53 (3): 524– 532. doi :10.1016/j.immuni.2020.07.020 . PMC 7392190 . PMID 32783920 .
^ "Personal LinkedIn page of Dr. Galit Alter" .
International National Academics